Biohaven Analyst Price Targets - Benzinga

Biohaven Ltd

BHVNNYSE

Trade with Public

Trade with Public

$15.61

0.452.97%

Últ. Act.: Nov 3, 4:25 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Biohaven Analyst Price Targets - Benzinga

Biohaven Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biohaven (BHVN).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

1S.Buy

12Buy

5Hold

1Sell

Consensus RatingBuy# Analysts19Avg. Consensus PT$33Upside to Avg. PT+118.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$19→$21
Oct 30, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$21→$32
Oct 23, 2026	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$19→$22
Sep 10, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$10
Sep 8, 2026	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$23→$19
Aug 12, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$18→$19
Aug 11, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$22→$23
Jun 29, 2026	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$12→$11
May 26, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$10
May 13, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$21→$18
May 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$23→$22
Apr 2, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$14→$17
Mar 11, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$15→$30
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Neutral	$11→$10
Mar 3, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$22→$23
Jan 21, 2026	RBC Capital	Leonid Timashev	Upgrade	Sector Perform→Outperform	$9→$22
Jan 6, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$26→$21
Dec 26, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$11
Dec 3, 2025	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$30→$11
Nov 26, 2025	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$26→$11

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32

Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Sector Perform and raises the price target from $19 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19

RBC Capital analyst Leonid Timashev downgrades Biohaven (NYSE:BHVN) from Outperform to Sector Perform and lowers the price target from $23 to $19.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.

Benzinga Newsdesk